LISATA THERAPEUTICS, INC. (LSTA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 15M 30M 45M Q3 '15: 14.9M Q4 '15: 14.9M Q1 '16: 19.3M Q2 '16: 21.7M Q3 '16: 25.1M Q4 '16: 35.3M Q1 '17: 35.7M Q2 '23: 0 Q3 '23: 0 Q4 '23: 0 Q1 '24: 0 Q2 '24: 0 Q3 '24: 0 Q4 '24: 1M Q1 '25: 1M Q2 '25: 1.1M Q3 '25: 1.1M Q4 '25: 170K Q1 '26: 170K Q2 '26: 100K Q4 '15 Q3 '16 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 7M 14M 21M Q4 '10: 20.2M Q1 '11: 20.5M Q2 '11: 14.4M Q3 '11: 9.5M Q4 '12: 2.4M Q1 '13: 1.7M Q2 '13: 1.2M Q3 '13: 1.2M Q4 '13: 1.7M Q4 '10 Q2 '11 Q4 '12 Q2 '13 Q4 '13

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -27.6M Q4 '21: -29.1M Q1 '22: -27.6M Q2 '22: -27.2M Q3 '22: -57.9M Q4 '22: -57.6M Q1 '23: -57.8M Q2 '23: -58M Q3 '23: -26.2M Q4 '23: -25.7M Q1 '24: -25.5M Q2 '24: -24.1M Q3 '24: -23.5M Q4 '24: -22.4M Q1 '25: -21.7M Q2 '25: -21M Q3 '25: -20.1M Q4 '25: -18.2M Q1 '26: -17.3M Q2 '26: -16.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '21: -26.1M Q4 '21: -27.5M Q1 '22: -23.6M Q2 '22: -24.6M Q3 '22: -55M Q4 '22: -54.2M Q1 '23: -56.2M Q2 '23: -53.6M Q3 '23: -21.5M Q4 '23: -20.8M Q1 '24: -20.1M Q2 '24: -21.1M Q3 '24: -20.7M Q4 '24: -20M Q1 '25: -19.3M Q2 '25: -18.9M Q3 '25: -18.2M Q4 '25: -16.6M Q1 '26: -16.4M Q2 '26: -14.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 15M 30M 45M Q2 '11: 42M Q3 '11: 32.6M Q4 '12: 11.9M Q1 '13: 11.4M Q2 '13: 12.9M Q3 '13: 12.1M Q4 '13: 12.9M Q1 '14: 14.4M Q2 '14: 13.8M Q3 '14: 14.9M Q4 '14: 15.7M Q1 '15: 15.2M Q2 '15: 17.3M Q3 '15: 18.1M Q4 '15: 20.2M Q1 '16: 23M Q2 '16: 24.3M Q3 '16: 28.1M Q4 '16: 31.1M Q1 '17: 33M Q3 '11 Q2 '13 Q1 '14 Q4 '14 Q3 '15 Q2 '16 Q1 '17

Operating Cash Flow TTM

-27M -18M -9M 0 9M 18M 27M Q3 '21: -23.2M Q4 '21: -22.2M Q1 '22: -19.9M Q2 '22: -20.3M Q3 '22: -19.3M Q4 '22: -21.2M Q1 '23: -23.7M Q2 '23: -22.8M Q3 '23: -22.4M Q4 '23: -20M Q1 '24: -18.9M Q2 '24: -20M Q3 '24: -18.9M Q4 '24: -19.4M Q1 '25: -17.7M Q2 '25: -16.4M Q3 '25: -17.2M Q4 '25: -15.9M Q1 '26: -13.6M Q2 '26: -12.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q2 '19: -18.1M Q3 '19: -17.7M Q4 '19: -18.9M Q1 '20: -17.6M Q2 '20: -8.4M Q3 '20: -7.5M Q4 '20: -8.8M Q1 '21: -12.6M Q2 '21: -21.8M Q3 '21: -23.3M Q4 '21: -22.3M Q2 '24: -20M Q3 '24: -18.9M Q4 '24: -19.4M Q1 '25: -17.8M Q2 '25: -16.4M Q3 '25: -17.3M Q4 '25: -16M Q1 '26: -13.6M Q2 '26: -12.3M Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 25M 50M 75M Q1 '20: 10.6M Q2 '20: 13.2M Q3 '20: 18.6M Q1 '21: 42.1M Q2 '21: 59.5M Q3 '21: 4M Q1 '22: 4M Q2 '22: 4M Q3 '22: 4.7M Q1 '23: 8M Q2 '23: 8M Q3 '23: 8.1M Q1 '24: 8.3M Q2 '24: 8.3M Q3 '24: 8.3M Q1 '25: 8.6M Q2 '25: 8.6M Q3 '25: 8.7M Q1 '26: 9M Q2 '26: 9.1M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-15.00 -10.00 -5.00 0.00 5.00 10.00 15.00 Q3 '21: -2.37 Q4 '21: -3.72 Q1 '22: -4.58 Q2 '22: -6.12 Q3 '22: -12.26 Q4 '22: -10.47 Q1 '23: -10.19 Q2 '23: -9.05 Q3 '23: -1.82 Q4 '23: -2.58 Q1 '24: -2.46 Q2 '24: -2.57 Q3 '24: -2.51 Q4 '24: -2.40 Q1 '25: -2.30 Q2 '25: -2.23 Q3 '25: -2.13 Q4 '25: -1.91 Q1 '26: -1.86 Q2 '26: -1.64 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.